Trump not joining WHO-backed coronavirus vaccine effort could hurt US


  • The Trump administration says the US won’t participate in COVAX, an international, WHO-backed effort to develop and distribute coronavirus vaccines. 
  • Trump has pledged to withdraw the US from the WHO entirely, calling the group’s pandemic response “China-centric.”
  • Health experts are concerned that the US’s absence from COVAX could impede the country’s access to vaccines developed in other countries. 
  • Visit Business Insider’s homepage for more stories.

When the World Health Organization announced COVAX last week — a major international effort to develop, manufacture, and distribute coronavirus vaccines — 172 countries had already signed on. 

One was conspicuously absent: the United States. 

Historically a global leader in fighting infectious diseases like HIV and smallpox, the US has distanced itself from the WHO since the pandemic began. In May, President Donald Trump announced the US would pull its funding and membership from the organization, an agency of the United Nations specializing in international public health issues. Trump called the WHO’s coronavirus response “China-centric.”

White House spokesman Judd Deere told Reuters on Tuesday that the US wouldn’t join COVAX because the WHO is “corrupt.” Instead, the Trump administration’s focus is on funding vaccine research and development on its own, then striking deals to buy the resulting shots. In the US so far, vaccine candidates developed by AstraZeneca and the University of Oxford, Moderna, and a Pfizer-BioNTech partnership have reached Phase 3 trials.

But COVAX is the only global initiative working with multiple countries to develop, manufacture, and distribute a coronavirus vaccine — and to make sure it reaches vulnerable populations, like the elderly and healthcare workers. The project’s larger goal is to have 2 billion vaccine doses by the end of 2021. That effort, which involves both governments and manufacturers, also aims to help wealthier countries distribute vaccines to poorer ones, thereby discouraging vaccine hoarding and ensuring all countries get access to a vaccine.

A lack of US collaboration undermines these goals, according to public-health experts. 

“The US has always been a leader in global health, going back to smallpox eradication, or polio eradication, or HIV,” Bill Gates, who’s helping to fund the GAVI Alliance, one of the organizations that’s leading COVAX, told Business Insider in July. “Without the US, the coalition to stop the disease globally just doesn’t come together.”

World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus.

World Health Organization Director-General Tedros Adhanom Ghebreyesus.

Fabrice COFFRINI/Getty Images

The US also needs the international community, experts say. Opting out of COVAX is a risky gamble, since it could limit the US’s access to vaccine candidates developed by other countries and manufacturing facilities abroad. If domestic vaccine candidates fail, in other words, the US could be out of luck. 

Plus, even if the US does make a successful vaccine on its own, some experts think that by staying out of COVAX, the country might hurt its own economy by not helping other countries get their populations properly protected and back to work.

“It’s a double edged sword,” Jennifer Huang Bouey, an epidemiologist and senior policy researcher at the RAND Corporation, told Business Insider. “It hurts the US, and it also probably hurts COVAX.” 

The US is betting on new, less-established types of vaccines

Globally, vaccine developers are testing at least eight different types of vaccine. The most established kind involves injections of weakened or inactivated virus to generate an immune response. 

The two strongest candidates in this traditional vein so far are from Chinese companies SinoPharm and SinoVac. (China also hasn’t signed on to COVAX, but gave the WHO a “positive signal” this week, according to Reuters.)

By refusing to participate in COVAX, Buoey said, the US “basically let go of the most traditional, most mature technology — that’s a risk.”

The US’s two strongest candidates so far, from Moderna and the Pfizer-BioNTech collaboration, are mRNA vaccines, a type that’s never been approved by the FDA before. These vaccines use a technology called messenger RNA to create doses using only a virus’ genetic code. 

Moderna coronavirus vaccine trial participant

Nurse Kath Olmstead gives volunteer Melissa Harting an injection as the world’s biggest study of a possible COVID-19 vaccine, developed by the NIH and Moderna, gets underway, July 27, 2020, in Binghamton, New York.

AP Photo/Hans Pennink

If successful, mRNA vaccines could be easier to produce and more effective than traditional ones, since they may prompt a stronger immune response and don’t need to be incubated the way traditional vaccines do. But that’s a big if — there’s still a possibility the mRNA vaccines will trigger inadequate immune responses or come with harmful side effects.

The US could lose access to international manufacturing

A big question authorities around the world are still tackling is how a vaccine will be manufactured and distributed after it’s proven to be safe and effective. The Coalition for Epidemic Preparedness Innovation (CEPI) — a foundation that funds vaccine research and is one of COVAX’s main backers — announced in June that it had identified enough vaccine manufacturers to produce 4 billion doses in a year. 

The US’s refusal to participate in COVAX means it could lack access to that infrastructure, though the country is working to expand its own manufacturing capacity. 

“It’s really just US versus all these other countries,” Buoey said. “The US will be left on its own.”

FILE PHOTO: Fujifilm's company logo (top) is seen at its exhibition hall nearby the headquarters of Fujifilm Holdings Corp in Tokyo, Japan June 12, 2017. REUTERS/Kim Kyung-Hoon/File Photo

Fujifilm received a $265 million grant to help expand US vaccine manufacturing capacity. The company logo is seen at an exhibition hall near its headquarters in Tokyo, Japan.


The US’s absence could limit COVAX’s potential manufacturing capacity as well — the initiative could distribute more vaccines if it had early access to successful candidates and facilities in the US. 

The US’s economy and reputation could suffer

Even if the US does create a successful vaccine, it could suffer economic repercussions if it hoards all the doses to itself, or if its supply chain can’t effectively distribute extra doses worldwide.

That’s because countries without a vaccine would continue to struggle with the economic impacts of COVID-19, and their economic fates are intertwined with the US’s. 

“We will continue to suffer the economic consequences — lost US jobs — if the pandemic rages unabated in allies and trading partners,” Thomas J. Bollyky, a senior fellow at the Council on Foreign Relations, told the Washington Post. 

Then there are larger, long-term questions about the US’s global reputation as a public-health leader, Buoey said, if the country stays out of international collaboration efforts. 

“Even during the height of the Cold War, US and Soviet Union scientists were working collaboratively with WHO on eradicating polio in 1950s to 1980s,” she said. “Right now, in the middle of the COVID pandemic, the US is really changing the track.”

Hilary Brueck contributed reporting.

Loading Something is loading.
Source link